This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
YY1 / Transcriptional repressor protein YY1 · IHC design guide
Design Immunohistochemistry for YY1
Plan paraffin-section YY1 IHC around the ubiquitous nuclear staining pattern reported in tissue (HPA tissue IHC). Use high-staining follicle cells or cytotrophoblasts as reference populations, and interpret staining with the reported cross-gene targeting caution (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
YY1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Ubiquitous nuclear staining in tissue (HPA tissue IHC) | |
| Staining pattern | Nuclear staining across tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M00833-3) | |
| Positive control | Ovary+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining may reflect proteins from more than one gene (HPA tissue IHC) | |
| Regulation | No staining-linked induction annotated (UniProt) | |
| Isoform / epitope | No annotated isoforms; one full-length chain (UniProt) |
Section 1
Recommended YY1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by three published YY1 IHC protocols for gastric and esophageal cancer tissues (PMC12754092; PMC3986816; PMC4196789).
| Sample | Paraffin-embedded human thyroid cancer tissue; fixative not specified (datasheet M00833-3) |
| Fixation | Image fixative and duration unreported (datasheet M00833-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M00833-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M00833-3) |
| Primary antibody | Mouse monoclonal (clone 3F3E7) anti-YY1, 2 μg/ml (datasheet M00833-3) |
| Primary incubation | Overnight at 4 °C (datasheet M00833-3) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M00833-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | YY1-positive staining in follicle cells of ovary (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet: M00833-3). The published protocols offer alternative retrieval conditions (PMC12754092; PMC3986816; PMC4196789).
Section 2
What Is the Expected YY1 Staining Pattern?
YY1 should appear mainly as nuclear staining in paraffin sections: UniProt places it at the nuclear matrix, and HPA reports ubiquitous nuclear expression with low tissue specificity (UniProt P25490 subcellular location; HPA tissue IHC). HPA rates its tissue pattern Supported, while cautioning that the staining antibody targets protein from more than one gene (HPA tissue IHC). Expect stronger signal in some cell populations than others (HPA tissue IHC).
| Nuclear chromogen in follicle cells, cytotrophoblasts, peritubular cells or urothelial cells. | This matches HPA's High staining in those populations and its ubiquitous nuclear profile (HPA tissue IHC). Judge each population against its own morphology and counterstain; a uniformly dark section alone does not establish cell-specific YY1 staining (standard IHC practice). |
| Predominantly cytoplasmic or surface staining, with little nuclear signal. | This conflicts with the reported nuclear matrix location and nuclear tissue pattern (UniProt P25490 subcellular location; HPA tissue IHC). Review compartment assignment against the counterstain and controls; nonspecific antibody binding or detection background is possible, but appearance alone cannot identify the cause (standard IHC practice). |
| Strong signal confined to an unexpected cell population while the expected nuclei are weak. | Check the tissue's HPA cell-level pattern before calling a mismatch: YY1 expression is broadly nuclear, and the supplied HPA list contains Low, not negative, populations (HPA tissue IHC). Persistent discordance may reflect cross-reactivity or endogenous detection activity; the image alone cannot distinguish them (standard IHC practice). |
| Haze or chromogen over nuclei, cytoplasm and surrounding section without clear cellular boundaries. | Diffuse staining prevents confident nuclear scoring (standard IHC practice). Assess a no-primary control for endogenous or reagent background, then review blocking, antibody dilution, washes and chromogen development as general IHC variables (standard IHC practice); HPA does not assign a YY1-specific cause (HPA tissue IHC). |
| No nuclear signal in an otherwise intact known-positive control section. | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. |
💡Expected YY1 appearanceCall the result positive when distinct nuclei in the relevant cells show chromogen, with stronger staining plausible in HPA High populations; predominant cytoplasmic color or diffuse section-wide deposits are suspect (HPA tissue IHC; UniProt P25490 subcellular location; standard IHC practice).
| Tissue and cell context | HPA reports High staining in ovarian follicle cells, placental cytotrophoblasts, testicular peritubular cells and bladder urothelial cells; neuronal cells in cerebral cortex and hepatocytes are Low, not negative (HPA tissue IHC). Compare like cell populations when judging intensity. |
| Antibody evidence and specificity | The HPA tissue profile is Supported but cautions that the staining antibody targets protein from more than one gene (HPA tissue IHC). HPA lists IHC as Supported for HPA001119 and CAB009392; that status supports their reported patterns without proving every stained nucleus is YY1 (HPA antibodies; HPA tissue IHC). |
| Cellular location and topology | UniProt associates YY1 with the nuclear matrix and records no transmembrane segment or signal peptide (UniProt P25490). Nuclear staining is therefore the primary compartment check; these annotations do not predict an antigen retrieval setting or a fixation response. |
| IF/ICC Q: What pattern is expected? | A: HPA reports mainly nucleoplasmic YY1, with additional signal at nucleoli fibrillar centers and nuclear bodies; its main and additional locations are Supported (HPA subcellular ICC-IF). This observation aids compartment comparison, but it is from ICC-IF, not paraffin-section IHC. |
| Situation | Likely cause | Next action |
|---|---|---|
| Positive-control tissue has no nuclear stain. | The control may lack the intended High cell population, or an IHC run step may have failed (HPA tissue IHC; standard IHC practice). | Confirm the relevant cells are present; check the antibody used, retrieval record and detection reagents with run controls before interpreting study sections (standard IHC practice). |
| Chromogen dominates the cytoplasm or cell edges. | That distribution conflicts with YY1's nuclear location; nonspecific binding or detection background is possible (UniProt P25490 subcellular location; standard IHC practice). | Compare stained cells with the nuclear counterstain and a no-primary control; review blocking, washes and detection conditions (standard IHC practice). |
| The entire section has diffuse color. | Background can obscure nuclear boundaries; the supplied HPA data do not establish a YY1-specific mechanism (HPA tissue IHC; standard IHC practice). | Inspect the no-primary control and review blocking, dilution, washes and chromogen development as general IHC checks (standard IHC practice). |
| A Low population stains faintly. | Low staining is reported for several populations, including hepatocytes and cortical neuronal cells; Low does not mean absent (HPA tissue IHC). | Assess nuclear localization and compare with a High population within the validated staining context; avoid treating faint signal alone as failure (HPA tissue IHC; standard IHC practice). |
| Unexpected cells show strong nuclear stain. | YY1 has a ubiquitous nuclear profile, but HPA cautions that the tissue-staining antibody targets protein from more than one gene (HPA tissue IHC). | Verify cell identity and compare the distribution with HPA's cell-level observations; use an independent specificity control before assigning unexpected staining to YY1 (HPA tissue IHC; standard IHC practice). |
| IF/ICC puncta are used to judge a chromogenic section. | HPA's supported nucleoli fibrillar center and nuclear-body observations come from ICC-IF images (HPA subcellular ICC-IF). | Use nuclear staining as the primary IHC compartment criterion; evaluate any finer pattern within the limits of the section and chromogenic readout (HPA tissue IHC; standard IHC practice). |
Experiment evidence
IHC & IF images showing YY1 staining
M00833-3 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-3). YY1 was detected in a paraffin-embedded section of human thyroid cancer tissue. Heat
M00833-3 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-3). YY1 was detected in a paraffin-embedded section of human laryngeal squamous cell car
M00833-3 · IFIF analysis of YY1 using anti-YY1 antibody (M00179-1). YY1 was detected in an immunocytochemical section of T-47D cells. Enzyme antigen retr
M00833-2 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-2). YY1 was detected in a paraffin-embedded section of human thyroid cancer tissue. Heat
M00833-2 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-2). YY1 was detected in a paraffin-embedded section of human pancreatic ductal adenocarc
M00833-1 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-1). YY1 was detected in a paraffin-embedded section of human laryngeal squamous cell car
M00833 · IHCImmunohistochemical analysis of paraffin-embedded human bladder using YY1 Antibody.
M00833 · IFImmunofluorescent analysis using the Antibody at 1:50 dilution.
PB9909 · IFIF analysis of YY1 using anti-YY1 antibody (PB9909). YY1 was detected in immunocytochemical section of A431 cells. Enzyme antigen retrieval
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000100811-YY1/tissue/cerebral+cortex#imid_375182
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000100811-YY1/tissue/colon#imid_375116
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000100811-YY1/tissue/liver#imid_375109
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000100811-YY1/tissue/kidney#imid_375110
HPA · ICC-IF REHHuman Protein Atlas immunofluorescence, REH, antibody HPA000597; green = YY1, blue = nucleus, red = microtubules.
HPA · ICC-IF REHHuman Protein Atlas immunofluorescence, REH, antibody HPA000597; green = YY1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for YY1 IHC & IF
🧪Run ovary first and score nuclear staining in follicle cells (HPA: High in ovary follicle cells; UniProt P25490: nuclear matrix). HPA detects YY1 in all 45 scored tissues and lists no negative tissue, so use no-primary and isotype controls; no cell population on the ovary slide is established as YY1-negative, and any apparently unstained cells should not be treated as a validated internal negative (HPA: no negative rows; YY1 detected in all 45 scored tissues).
Positive control tissue: Ovary (Follicle cells, HPA High)
Negative control tissue: None in HPA: YY1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show YY1 in REH, Rh30, U2OS, A-431, U-251MG, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and a concentration-matched mouse IgG isotype control for the mouse catalog antibody; where available, use a YY1 knockout sample or peptide-blocked antibody as a biological specificity control (selected-SKU caption: mouse anti-YY1; standard IHC practice). For chromogenic detection in ovary, quench endogenous peroxidase and check background before interpreting nuclear DAB staining (selected-SKU caption: HRP/DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU thyroid cancer paraffin-section caption does not state the fixative (selected-SKU caption: fixative not stated). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish that YY1 staining depends on that retrieval condition (selected-SKU caption: EDTA pH 8.0). HPA reports supported nucleoplasmic ICC-IF localization, but the supplied evidence does not establish that IF or frozen sections are easier than paraffin IHC or identify an ovary-specific artefact; assess background on the ovary control slides (HPA: subcellular localization; standard IHC practice).
HPA tissue IHC evidence for YY1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Ovary | Follicle cells | High | Protein (IHC) | HPA → |
| Placenta | Cytotrophoblasts | High | Protein (IHC) | HPA → |
| Testis | Peritubular cells | High | Protein (IHC) | HPA → |
| Urinary bladder | Urothelial cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: YY1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced YY1 IHC Tips
Troubleshoot YY1 staining in paraffin sections by checking nuclear localisation, specimen processing and controls before comparing staining intensity.
How should I adjust retrieval when YY1 nuclear staining is weak?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 (datasheet M00833-3). The selected paraffin-section example used that retrieval before incubation with 2 μg/ml primary antibody overnight at 4°C (datasheet M00833-3). If nuclei remain weak, verify heating consistency and section adherence, then compare a more vigorous retrieval run on adjacent sections while keeping antibody and detection conditions fixed (standard IHC practice). Use a known staining section in each run to distinguish retrieval failure from specimen variation (standard IHC practice). Judge improvement by nuclear signal and tissue preservation together, because damaged morphology makes compartment scoring unreliable (standard IHC practice).
Could fixation explain variable YY1 staining across paraffin sections?
The selected paraffin-section caption does not state a fixative, so target-specific YY1 fixation sensitivity is unknown (datasheet M00833-3). Record each specimen's fixative, fixation duration and processing history before comparing nuclear staining across cases (standard IHC practice). Compare serial sections processed together, using the same pH 8.0 EDTA retrieval and detection settings, to limit technical variation (datasheet M00833-3; standard IHC practice). Check morphology for poor preservation or excessive processing before changing primary antibody concentration (standard IHC practice). A staining difference alone cannot establish a YY1-specific fixation effect; confirm it with specimens whose processing histories are documented (standard IHC practice).
What staining pattern should count as YY1 positive in IHC?
Prioritise staining within intact nuclei: tissue IHC reports ubiquitous nuclear expression, and subcellular data place YY1 mainly in the nucleoplasm (HPA tissue IHC; HPA subcellular). Nuclear bodies and nucleolar fibrillar centres are additional reported locations, while UniProt associates YY1 with the nuclear matrix (HPA subcellular; UniProt P25490 subcellular). Assess chromogen against a counterstain so nuclear boundaries remain visible (standard IHC practice). Do not score isolated cytoplasmic pigment as convincing YY1 without corroborating nuclear staining and appropriate controls (HPA tissue IHC; standard IHC practice). Compare staining in the relevant cell population rather than interpreting every dark deposit in the section as positive (standard IHC practice).
How can epitope access or sequence variation affect YY1 IHC?
The supplied UniProt record lists a single 1–414 chain and 0 annotated isoforms; this does not establish which epitope the catalog antibody recognises (UniProt P25490 processing and isoforms). It lists phosphorylation at residues 118, 187, 247 and 378, without showing whether those modifications affect this antibody's binding (UniProt P25490 modified residues). If staining varies unexpectedly, obtain the antibody's immunogen or epitope information before attributing the change to a specific residue (standard IHC practice). Compare retrieval conditions on matched sections while holding incubation and detection constant (standard IHC practice). Treat a shifted nuclear staining pattern as an observation requiring validation, rather than evidence of an unannotated isoform (standard IHC practice).
How should I adapt YY1 assessment for multiplex IF?
Design the secondary IF assay around nuclear YY1: subcellular data place it mainly in the nucleoplasm, and UniProt reports no transmembrane segment (HPA subcellular; UniProt P25490 topology). Optimise permeabilisation for access to the nuclear epitope, checking nuclear morphology as conditions change (standard IF practice). Pair YY1 with a validated marker for the cell population being assessed; follicle cells in ovary and cytotrophoblasts in placenta are reported as high staining populations (HPA tissue IHC; standard IF practice). Choose fluorophores after inspecting specimen autofluorescence and include single-stain controls for channel separation (standard IF practice). Establish IF antibody performance independently; the selected product caption documents chromogenic paraffin-section IHC (datasheet M00833-3).
What causes diffuse brown background around otherwise positive YY1 nuclei?
First compare the deposits with nuclear boundaries: YY1 is reported as ubiquitously nuclear in tissue and mainly nucleoplasmic in subcellular data (HPA tissue IHC; HPA subcellular). The selected example used 10% goat serum blocking, a peroxidase-conjugated secondary antibody and DAB detection (datasheet M00833-3). Check a no-primary control, endogenous peroxidase blocking and wash quality to identify nonspecific chromogen deposition (standard IHC practice). Titrate the primary antibody around the documented 2 μg/ml condition if background persists, preserving the same retrieval and exposure settings during comparison (datasheet M00833-3; standard IHC practice). Exclude pigment over necrotic or damaged areas from nuclear scoring (standard IHC practice).
How should I quantify YY1 across sections with different cell densities? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and count only nuclei with interpretable morphology, consistent with YY1's nuclear tissue profile (HPA tissue IHC; standard IHC practice). Report the percentage of positive nuclei among all evaluable nuclei in that population, or use an H-score based on intensity categories 0–3 for a 0–300 range (standard IHC practice). If spatial abundance matters, report positive nuclei per mm² alongside total nuclei per mm² (standard IHC practice). Keep counterstain, illumination and scoring thresholds consistent across sections (standard IHC practice). Compare matched anatomical compartments, since HPA reports high staining in some cell populations and low staining in others (HPA tissue IHC).
How do I distinguish genuine YY1 staining from artefact?
Genuine staining should align with intact nuclei; HPA reports ubiquitous nuclear tissue expression and mainly nucleoplasmic subcellular localisation (HPA tissue IHC; HPA subcellular). Check whether the stained cells match the intended compartment: HPA reports high staining in ovarian follicle cells and low staining in liver hepatocytes (HPA tissue IHC). Treat staining confined to section edges, necrotic regions or damaged folds as suspect until it reproduces in well-preserved areas (standard IHC practice). Use a no-primary control and adequate peroxidase blocking to evaluate endogenous enzyme signal in a DAB workflow (standard IHC practice). Interpret unexpectedly widespread or cytoplasmic deposits cautiously because the HPA tissue assay warns that its antibody targets protein from more than one gene (HPA tissue IHC).
Boster reagents
Best YY1 / Transcriptional repressor protein YY1 IHC Antibodies
Anti-YY1 antibodies have images from human paraffin-section IHC and A431-cell IF (catalog image captions); catalog reactivity fields list human, mouse and rat.
Real IHC data
Anti-YY1 Antibody ® (monoclonal, 3F3E7)
Cat # M00833-3
Real IHC data
Anti-YY1 Antibody ® (monoclonal, 2C10F9)
Cat # M00833-2
Real IHC data
Anti-YY1 Antibody ® (monoclonal, 6H3E1)
Cat # M00833-1
Real IHC data
Anti-YY1 Rabbit Monoclonal Antibody
Cat # M00833
Real IF data
Anti-YY1 Antibody ®
Cat # PB9909
M00833-3 and M00833-2 show IHC in human thyroid cancer paraffin sections (respective IHC captions); M00833-1 shows IHC in a human laryngeal squamous cell carcinoma paraffin section (M00833-1 IHC caption). M00833 shows IHC in paraffin-embedded human bladder (M00833 IHC caption); PB9909 shows IF in A431 cells (PB9909 IF caption).
Which to pick: For tissue IHC, choose mouse monoclonal M00833-2: its captions document human paraffin sections from four tissue types with EDTA pH 8 retrieval (M00833-2 catalog and IHC captions); the fixative is unreported (M00833-2 IHC captions). For IF/ICC, choose PB9909, which has an A431-cell IF image and listed IF/ICC applications (PB9909 IF caption and application list). For cross-species planning, rabbit monoclonal M00833 lists human, mouse and rat reactivity plus IHC/ICC/IF applications (M00833 catalog); its paraffin-embedded bladder image documents human tissue only, and the fixative is unreported (M00833 IHC caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P25490 (TYY1_HUMAN, Transcriptional repressor protein YY1).
- Human Protein Atlas. YY1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. YY1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the nucleoli fibrillar center and nuclear bodies..
- Human Protein Atlas. YY1 antibody validation summary (3 antibodies).
- YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice. Nature communications 2025 — PMC12234789.
- Yin Yang 1 activates JAK-STAT3-mediated epithelial-mesenchymal transition in Helicobacter pylori-induced gastric cancer progression. World journal of clinical oncology 2025 — PMC12754092.
- Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. Journal of translational medicine 2014 — PMC3986816.
- Expression of YY1 correlates with progression and metastasis in esophageal squamous cell carcinomas. OncoTargets and therapy 2014 — PMC4196789.
- PubMed PMID:1655281 — UniProt-cited evidence.
- PubMed PMID:1946405 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for YY1 (Transcriptional repressor protein YY1). Expected localisation Ubiquitous nuclear staining in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M00833-3). Validated IHC antibody: M00833-3 at 2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Ovary (Follicle cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human thyroid cancer tissue; fixative not specified (datasheet M00833-3); 2. Fixation: Image fixative and duration unreported (datasheet M00833-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M00833-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M00833-3); 8. Primary antibody: Mouse monoclonal (clone 3F3E7) anti-YY1, 2 μg/ml (datasheet M00833-3); 9. Primary incubation: Overnight at 4 °C (datasheet M00833-3). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining may reflect proteins from more than one gene (HPA tissue IHC); Isoform / epitope: No annotated isoforms; one full-length chain (UniProt); Regulation: No staining-linked induction annotated (UniProt). Evidence: UniProt P25490, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M00833-3, PMC12754092, PMC3986816. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/YY1/immunohistochemistry-ihc-guide.